Detalhe da pesquisa
1.
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
Br J Cancer
; 125(10): 1365-1376, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34588615
2.
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.
Lung Cancer
; 189: 107502, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38359742
3.
Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.
Int J Cancer
; 133(4): 898-907, 2013 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23400671
4.
MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.
Cell Rep Med
; 4(4): 101006, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37044092
5.
Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes.
Breast Cancer Res Treat
; 132(3): 979-92, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21735045
6.
Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer.
Cancer Treat Rev
; 109: 102430, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35777135
7.
Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH.
Hum Mutat
; 32(1): 78-90, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21031597
8.
Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors.
Hum Mutat
; 32(2): E1999-2017, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21280140
9.
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade.
Nat Commun
; 12(1): 4319, 2021 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34262032
10.
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
Hum Mutat
; 30(3): 454-62, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19241459
11.
Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations.
Hum Mutat
; 29(9): E173-93, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18546366
12.
Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.
Oncotarget
; 9(59): 31549-31558, 2018 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-30140389
13.
MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.
Clin Cancer Res
; 24(18): 4579-4587, 2018 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898990
14.
Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.
Mol Cancer Ther
; 16(7): 1366-1376, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28396363
15.
Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.
Clin Cancer Res
; 23(12): 3203-3213, 2017 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28302866
16.
NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing.
Hum Mutat
; 27(11): 1104-14, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16937374
17.
MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.
Cancer Discov
; 4(3): 292-303, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24362264
18.
Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment.
Eur J Hum Genet
; 18(5): 614-7, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19935827
19.
Tumor LOH analysis provides reliable linkage information for prenatal genetic testing of sporadic NF1 patients.
Genes Chromosomes Cancer
; 46(9): 820-7, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17563086